Print Magazine
Brussels Morning Newspaper
Sunday, February 5, 2023
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home EU Institutions

EU Medicines Agency to speed up coronavirus vaccine approval

Nikola Kiš by Nikola Kiš
2 October 2020
in EU Institutions, Features
EU Medicines Agency to speed up coronavirus vaccine approval
Share on FacebookShare on Twitter

The EU Medicines Agency (EMA) has begun reviewing the coronavirus vaccine being developed by Oxford University and AstraZeneca in hopes of speeding up its potential approval, AP reported yesterday, Thursday.

Rather than await submission of all the required data, the EMA announced it was starting its analysis of preliminary data on the Oxford vaccine. The agency declared that it hoped to receive data from late-stage tests in the coming weeks and months, but that meanwhile its rolling review would continue as enough evidence is available to support authorization.

The EMA said the review process should be quicker than the routine evaluative approach. It pointed out how remdesivir, one of the few licensed drugs for treating coronavirus infections, had been approved through a similarly speeded up process in just over one month. According to preliminary findings, the vaccine triggers a strong immune response and is safe, but longer-term data is needed.

AstraZeneca has signed private deals to provide vaccines to Canada, France, Germany, the UK and the US, with first deliveries expected even before the vaccine is licensed.

Trials of the Oxford vaccine are underway in the UK and the US, with the US trials awaiting clearance from the Food and Drug Administration before being given the green light to continue. Other vaccines are undergoing late-stage testing in several hard-hit countries including Brazil, China, Russia as well as the US.

Last week, the World Health Organisation noted that some countries are struggling to secure enough flu vaccine with the approach of the flu season. Italy has lowered the age limit for receiving free flu vaccine from 65 to 60. Pharmacists and doctors are expressing concern about the supply. France has ordered 30% more flu vaccine compared to last year and is prioritizing high-risk groups. In Germany, Health Minister Jens Spahn has said he would be very happy if all 26 million flu doses were used. Germany usually buys between 18 and 19 million doses.

SOURCE

Tweets by EMA_News
Tweets by UniofOxford
Tweets by AstraZeneca
Tweets by WHO
Tweets by jensspahn
Tags: EU Medicines AgencyVaccinationVaccine
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • Health & Fitness
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • Brussels Bubble
    • Parliament
    • Commission
    • Council
  • Wider Europe
    • Member States
  • World
  • Business & Society
  • Europe With Transparency
  • Culture & Society
  • Policy Talks
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • Ambassador’s Corner
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT